BRPI0417126A - partìcula viral constituìda de elementos estruturais não provenientes de um alfa-vìrus e contendo um vetor derivado de alfa-vìrus, utilização da partìcula viral e processo de obtenção de partìculas virais - Google Patents

partìcula viral constituìda de elementos estruturais não provenientes de um alfa-vìrus e contendo um vetor derivado de alfa-vìrus, utilização da partìcula viral e processo de obtenção de partìculas virais

Info

Publication number
BRPI0417126A
BRPI0417126A BRPI0417126-8A BRPI0417126A BRPI0417126A BR PI0417126 A BRPI0417126 A BR PI0417126A BR PI0417126 A BRPI0417126 A BR PI0417126A BR PI0417126 A BRPI0417126 A BR PI0417126A
Authority
BR
Brazil
Prior art keywords
alpha virus
viral
structural elements
viral particle
derived
Prior art date
Application number
BRPI0417126-8A
Other languages
English (en)
Inventor
Jean-Christophe Pages
Original Assignee
Parthenios Teni Boulikas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parthenios Teni Boulikas filed Critical Parthenios Teni Boulikas
Publication of BRPI0417126A publication Critical patent/BRPI0417126A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PARTìCULA VIRAL CONSTITUìDA DE ELEMENTOS ESTRUTURAIS NãO PROVENIENTES DE UM ALFA-VìRUS E CONTENDO UM VETOR DERIVADO DE ALFA-VìRUS, UTILIZAçãO DA PARTìCULA VIRAL E PROCESSO DE OBTENçãO DE PARTìCULAS VIRAIS Trata-se o presente invento, de uma partícula viral constituída de elementos estruturais não provenientes de um alfa-vírus e contendo um vetor derivado de alfa-vírus tornado defectivo para a replicação, por supressão ou substituição por no mínimo um transgene, de genes estruturais caracterizada pelo fato de que os elementos estruturais da referida partícula não são codificados pelo genoma do vetor derivado do alfa-vírus, procedido de produção da referida partícula que consiste em exprimir em <i>trans</i>, em uma linha celular, os genes que codificam os elementos estruturais não emitidos do alfa-vírus e o vetor derivado de alfa-vírus e a recuperar as partículas virais presentes no sobrenadante da cultura celular.
BRPI0417126-8A 2003-12-02 2004-11-30 partìcula viral constituìda de elementos estruturais não provenientes de um alfa-vìrus e contendo um vetor derivado de alfa-vìrus, utilização da partìcula viral e processo de obtenção de partìculas virais BRPI0417126A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0350951A FR2862982B1 (fr) 2003-12-02 2003-12-02 Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale.
PCT/FR2004/050631 WO2005056805A1 (fr) 2003-12-02 2004-11-30 Particules virales contenant un vecteur derive d'alpha virus et procede de preparation de ladite particule virale

Publications (1)

Publication Number Publication Date
BRPI0417126A true BRPI0417126A (pt) 2007-12-11

Family

ID=34566388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417126-8A BRPI0417126A (pt) 2003-12-02 2004-11-30 partìcula viral constituìda de elementos estruturais não provenientes de um alfa-vìrus e contendo um vetor derivado de alfa-vìrus, utilização da partìcula viral e processo de obtenção de partìculas virais

Country Status (11)

Country Link
US (1) US20080118956A1 (pt)
EP (1) EP1697529A1 (pt)
JP (1) JP2007512827A (pt)
KR (1) KR20070085044A (pt)
CN (1) CN101006180A (pt)
AU (1) AU2004297379A1 (pt)
BR (1) BRPI0417126A (pt)
CA (1) CA2547922A1 (pt)
FR (1) FR2862982B1 (pt)
RU (1) RU2398875C2 (pt)
WO (1) WO2005056805A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040023A2 (en) 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
EP2831225A1 (en) * 2012-03-26 2015-02-04 The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer Delivery of packaged rna to mammalian cells
AU2014365777B2 (en) * 2013-12-16 2020-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
CN105176936B (zh) * 2015-10-23 2019-01-11 中国科学院武汉物理与数学研究所 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用
WO2017083356A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
US20230063041A1 (en) * 2020-01-10 2023-03-02 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1998013511A1 (en) * 1996-09-25 1998-04-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
FI20020375A (fi) * 2002-02-27 2003-08-28 Wahlfors Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt

Also Published As

Publication number Publication date
FR2862982B1 (fr) 2006-04-28
FR2862982A1 (fr) 2005-06-03
JP2007512827A (ja) 2007-05-24
AU2004297379A1 (en) 2005-06-23
US20080118956A1 (en) 2008-05-22
WO2005056805A1 (fr) 2005-06-23
KR20070085044A (ko) 2007-08-27
RU2398875C2 (ru) 2010-09-10
CN101006180A (zh) 2007-07-25
EP1697529A1 (fr) 2006-09-06
CA2547922A1 (en) 2005-06-23
RU2006123079A (ru) 2008-01-10

Similar Documents

Publication Publication Date Title
Han et al. Epiblast stem cell subpopulations represent mouse embryos of distinct pregastrulation stages
Lulla et al. Macromolecular assembly-driven processing of the 2/3 cleavage site in the alphavirus replicase polyprotein
Yount et al. Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome
Khaperskyy et al. Timing is everything: coordinated control of host shutoff by influenza A virus NS1 and PA-X proteins
Goodfellow et al. Structure and function analysis of the poliovirus cis-acting replication element (CRE)
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
JP2016539627A5 (pt)
UY28867A1 (es) Factor de permisividad celular para virus y usos del mismo
Lin et al. Micro RNA s in Marchantia polymorpha
CO6551678A2 (es) Contructo para la producción de capsides picornavirales vacias
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
Kotini et al. Escape mutations, ganciclovir resistance, and teratoma formation in human iPSCs expressing an HSVtk suicide gene
Moreno et al. Exploration of sequence space as the basis of viral RNA genome segmentation
BRPI0417126A (pt) partìcula viral constituìda de elementos estruturais não provenientes de um alfa-vìrus e contendo um vetor derivado de alfa-vìrus, utilização da partìcula viral e processo de obtenção de partìculas virais
MX2018006373A (es) Produccion de virus en cultivos celulares.
ATE454039T1 (de) Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung
Atieh et al. New reverse genetics and transfection methods to rescue arboviruses in mosquito cells
BR0214489A (pt) Processo para a produção de um polipeptìdeo recombinante
PH12020500503A1 (en) A method for producing banana plants with tolerance to fusarium oxysporum cubensis tr4
BR112020012190A8 (pt) Partícula de replicon de alfavírus
EA201690232A1 (ru) Генетически стабильный онколитический рнк вирус, способ его производства и применения
MX2021013223A (es) Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
Oh et al. Multi-resistance strategy for viral diseases and in vitro short hairpin RNA verification method in pigs
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
JP2016519575A5 (pt)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15Z Prolongation of time limit refused

Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO UMA VEZ QUE NAO FICOU COMPROVADA A JUSTA CAUSA CONFORME DEFINIDA NO ART. 221 DA LPI.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]